Description
Iv0049 is a humanized monoclonal antibody that targets and neutralizes interferon-gamma (IFN-γ), a cytokine associated with inflammatory pathways. It has been investigated for potential use in autoimmune diseases such as Crohn’s disease. By binding IFN-γ, Iv0049 reduces downstream inflammatory signaling and its detrimental effects on intestinal barrier integrity. Early clinical studies have reported signs of therapeutic activity and generally manageable tolerability, although some serious adverse events, including disease exacerbation, were observed. Iv0049 has not been described as a currently marketed therapy, and its broader clinical development status remains unclear.